Adam Gridley, President and Chief Executive Officer
Mr. Gridley joined Histogenics in 2014, and has more than 20 years of experience in the medical device, biotechnology and pharmaceutical industries. Before joining the Histogenics team, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquisition by Merz. Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a B.S. and a M.B.A. from the University of Denver.
Stephen Kennedy, Executive Vice President & Chief Operating Officer
Mr. Kennedy joined Histogenics in 2013, and has more than 30 years of experience in biological manufacturing and process development, including 18 years at Genzyme Corporation, where he had a strong history of company development and delivering process and organizational performance improvements resulting in increased profit. As Genzyme’s Senior Vice President of Biologics Technical Operations, he developed cGMP biologics manufacturing operations at facilities in Belgium and France, oversaw Genzyme’s gene therapy operation in San Diego, and formed the global Biologics Operations organization. Before this, Mr. Kennedy developed the manufacturing process optimization organization that supported Genzyme’s full range of products, including all biologics, Carticel® and hyaluronic acid products, such as Seprafilm®. Early in his career at Genzyme, Mr. Kennedy focused on implementation and optimization of cell culture manufacturing technologies used in the production of flagship products at Genzyme, including Ceredase® and Cerezyme®. He has also served as Executive Director of the Novartis/MIT Center for Continuous Manufacturing at the Massachusetts Institute of Technology. Mr. Kennedy has a B.S. from the University of Michigan, an M.S. from the University of Rochester and an M.B.A. from Boston University.
Jon Lieber, Chief Financial Officer
Mr. Lieber joined Histogenics in 2015, and has more than 20 years of experience in financial and executive management at emerging growth, life sciences companies and in investment banking. Prior to Histogenics, Mr. Lieber most recently served as the CFO of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, as the CFO and Treasurer of Repligen Corporation, a publicly held manufacturer and supplier of high-value consumables to the life sciences industry, and the CFO of Xcellerex Inc. (acquired by GE Healthcare), a company engaged in the manufacture and sale of capital equipment and related consumables to the life sciences industry. Previously, Mr. Lieber served as the CFO of Altus Pharmaceuticals where he led all public and private capital raising activities at the company, including its $110 million initial public offering and a subsequent $90 million follow-on offering. Prior to joining Altus, Mr. Lieber was an investment banker for 10 years where he originated and executed on numerous corporate financings and merger and acquisition transactions at SG Cowen and Salomon Brothers Inc. He received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University Stern School of Business.
Caroline Dugopolski, VP of Technical Operations
Mrs. Dugopolski joined Histogenics in 2014, and has more than 15 years of experience supporting cGMP biopharmaceutical manufacturing operations in both technical and quality roles. She leads the Histogenics program team responsible for manufacturing, testing, and disposition of the NeoCart® product to support the success of our Phase 3 clinical trial. Prior to joining Histogenics, Caroline spent thirteen years at Genzyme Corporation where she initially held roles focused on process engineering and team leadership in providing technical support for large-scale commercial biologics manufacturing. Her work primarily focused on manufacturing and technology for Genzyme’s core enzyme replacement therapy products (Cerezyme®, Fabrazyme®, and Myozyme®). Caroline was responsible for addressing production issues, analyzing process performance, and implementing process improvements. Caroline transitioned into a Quality Program Management role in which she made critical contributions to close quality system gaps. She led cross-functional teams through the design, implementation, and operation of remediated quality systems to enable successful completion of Genzyme’s work plan to improve quality systems at its Allston Landing Facility. Caroline has a B.S.E. in chemical engineering and a M.S. in biomedical engineering from the University of Michigan.
Peter Hamilton, VP of Operations & Engineering
Mr. Hamilton joined Histogenics in 2011 as Vice President, Manufacturing and Production, and has over 25 years of experience in manufacturing, engineering and technical roles. Prior to joining Histogenics, Mr. Hamilton served as Vice President Operations for Choice Therapeutics, Inc., a startup wound care company specializing in antimicrobial dressings using silver nylon. Mr. Hamilton served as the Operations Manager at BioSphere Medical from February 2000 until June 2007. Mr. Hamilton was a Senior Development Engineer at Boston Scientific, from 1991 through 2000. Mr. Hamilton served as a Design Engineer at Deknatel from 1988 until 1991. Mr. Hamilton is the holder of sixteen U.S. patents. He holds a B.S. from Wentworth Institute of Technology and an M.B.A. from Anna Maria College.
Harris Shuman, VP of Finance
Mr. Shuman joined Histogenics in 2015, and has more than 25 years of experience in technical accounting, controlling, and financial management roles. Prior to Histogenics, he most recently served as Director of Finance and Accounting at Epizyme, Inc., which he joined in 2010. There, he was instrumental in getting the company IPO-ready leading to the company’s successful IPO in 2013. He also led all finance activities as it related to its multiple collaborations. Prior to working at Epizyme, Mr. Shuman served in strategic and financial management roles at Virgin HealthMiles, a Virgin Group company and Oxigene, Inc. Before, Mr. Shuman worked in a number of startup companies in a financial capacity after he started his career in Public Accounting at Laventhol & Horwath. Mr. Shuman is a CPA licensed in Massachusetts. He received his B.S. in accounting from University of Massachusetts and his M.S.F from Bentley University.
Eric Blahut, Senior Director, Manufacturing
Mr. Blahut began his career by working for the technical co-founder of Histogenics, Dr. Shuichi Mizuno, at the Brigham and Women’s Hospital in Boston. He joined Histogenics as a research associate when the company was founded in the year 2000. In the years since, he has been instrumental in the development of the NeoCart product and testing methods. Mr. Blahut’s contributions to Histogenics have ranged from product development to surgeon trainings and regulatory filings. He manufactured the first NeoCart implant for the Phase 1 clinical trial and then went on to oversee Phase 2 and Phase 3 clinical manufacturing. As the longest tenured employee at Histogenics, Mr. Blahut holds the honor of being the un-official historian of the company. He received a B.S. in animal science from the University of Massachusetts Amherst.
Sheila Boyce, Senior Director Facilities and Engineering
Prior to joining Histogenics in 2014, Mrs. Boyce was the lead engineer on multiple successful projects at Genzyme Corporation, most notably the scale-up and commercialization of hyaluronic acid based Seprafilm® and development and implementation of the terminal viral inactivation process for ATryn®, the first therapeutic agent produced using transgenic animals to gain FDA approval. During her fifteen years at Genzyme Corporation, Mrs. Boyce was the recipient of two Genzyme Corporation Vice President’s Awards recognizing outstanding dedication and contribution to the success of a program. She currently serves on the Northeastern University Bioengineering Industrial Advisory Board. She has a B.S. in Chemical Engineering from Northeastern University.
Photo credit: Tatiana Blanco Photography